Study details
Enrolling now
Phase I/II Trial of NBTXR3 with Radiation and Immunotherapy
M.D. Anderson Cancer Center
NCT IDNCT05039632ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1/2
Target enrollment
40
Study length
about 2.7 years
Ages
18+
Locations
1 site in TX
About this study
This trial is testing a new treatment called NBTXR3, radiation therapy, and immunotherapy (Anti-PD-1/L-1) in people with advanced solid tumors that have spread to the lung or liver. The goal is to see if this combination can help control the disease.
Based on ClinicalTrials.gov records.
What participants do
- 1.Hafnium Oxide-containing Nanoparticles NBTXR3
- 2.Receive Radiation Therapy
PhasePhase 1/Phase 2
Primary goalIncidence of dose limiting toxicities
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Incidence of dose limiting toxicities, Objective response rate
Procedures
radiation